Samsara Therapeutics
Michael Schlossmacher MD is Professor in Neurology at the University of Ottawa in Canada. After his medical education in Vienna and postgraduate studies on Alzheimer’s disease at Harvard University, he pursued clinical training at Brigham & Women’s Hospital and Massachusetts General Hospital in Boston. Since 2000, he has focused his research activities on Parkinson’s disease, first at the Center for Neurologic Diseases at Brigham & Women’s Hospital and Harvard Medical School. Since 2006, he has been based at the University of Ottawa, where he co-directs the Parkinson’s Research Consortium. In 2012, he was named the Bhargava Research Chair in Neurodegeneration at the Ottawa Hospital Research Institute; in 2015, he was appointed director of its Neuroscience Program.
This person is not in the org chart
This person is not in any offices
Samsara Therapeutics
Samsara Therapeutics, Inc. is a biopharmaceutical company aiming to discover the first-in-class therapeutics that treat rare genetic and neurodegenerative diseases and extend a healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy.